Evidence map›Paper›PMID 38637512›Full record

ArticleNature communications2024

RNA targeting and cleavage by the type III-Dv CRISPR effector complex.

Evan A Schwartz, Jack P K Bravo, Mohd Ahsan, Luis A Macias, Caitlyn L McCafferty, Tyler L Dangerfield, Jada N Walker, Jennifer S Brodbelt, Giulia Palermo, Peter C Fineran and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Structural mechanism of SAM-AMP and SAM-AMPNature communications · 2026
    Article
  3. From pond to platform: howJournal of bacteriology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Evan A Schwartz *Interdisciplinary Life Sciences Graduate Programs, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-7468-9010
Jack P K Bravo *Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0003-0456-0753
Mohd Ahsan *Department of Bioengineering and Department of Chemistry, University of California, Riverside, CA, USA.ORCID http://orcid.org/0000-0002-0583-4413
Luis A MaciasDepartment of Chemistry, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0003-1949-6029
Caitlyn L McCaffertyInterdisciplinary Life Sciences Graduate Programs, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-0872-4527
Tyler L DangerfieldDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0003-1413-2082
Jada N WalkerDepartment of Chemistry, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0001-6233-3124
Jennifer S BrodbeltDepartment of Chemistry, University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0003-3207-0217
Giulia PalermoDepartment of Bioengineering and Department of Chemistry, University of California, Riverside, CA, USA. gpalermo@engr.ucr.edu.ORCID http://orcid.org/0000-0003-1404-8737
Peter C FineranMicrobiology and Immunology, University of Otago, PO Box 56, Dunedin, New Zealand.ORCID http://orcid.org/0000-0002-4639-6704
Robert D FagerlundMicrobiology and Immunology, University of Otago, PO Box 56, Dunedin, New Zealand. robert.fagerlund@otago.ac.nz.ORCID http://orcid.org/0000-0002-3939-1489
David W TaylorInterdisciplinary Life Sciences Graduate Programs, University of Texas at Austin, Austin, TX, USA. dtaylor@utexas.edu.ORCID http://orcid.org/0000-0002-6198-1194
The University of Texas at Austin · USUniversity of California, Riverside · USUniversity of Otago · NZLivestrong Foundation · US

Funding

Ultraviolet Photodissociation Mass Spectrometry for Characterization of Biological MoleculesR35GM139658 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI BRODBELT, JENNIFER S. · 2021 to 2025
$2.9M
Imaging macromolecular machines in gene regulationR35GM138348 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI TAYLOR, DAVID W · 2020 to 2024
$1.9M
Investigating the metal-dependent function, allostery and inhibition of CRISPR-Cas9R01GM141329 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI PALERMO, GIULIA · 2021 to 2025
$1.7M
Implementing Photodissociation Mass Spectrometry to study Disease and Lipid StructureF31CA257404 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI MACIAS, LUIS A · 2021 to 2022
$49k
NCI NIH HHS F31 CA257404NIGMS NIH HHS R01 GM141329NIGMS NIH HHS R35 GM138348NIGMS NIH HHS R35 GM139658
6 · The paper itself

Abstract

CRISPR-Cas are adaptive immune systems in bacteria and archaea that utilize CRISPR RNA-guided surveillance complexes to target complementary RNA or DNA for destruction

Indexed as

CRISPR-Associated ProteinsRNA, CatalyticCatalytic DomainCRISPR-Cas SystemsDNARNARNA CleavageCRISPR-Associated ProteinsDNARNARNA, Catalytic

Identifiers

PMID38637512
PMCPMC11026444
OpenAlexW4394927053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.